Literature DB >> 2901518

Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.

G G Jackson1, J T Perkins, M Rubenis, D A Paul, M Knigge, J C Despotes, P Spencer.   

Abstract

Infusions of 55-500 ml plasma from one of two donors selected for high anti-p24 antibody titre and neutralising capacity were given to six patients with advanced AIDS. Human immunodeficiency virus (HIV) antigenaemia cleared immediately and the recipients' serum acquired the HIV antibody profile of the donor together with HIV neutralising activity. The passive antibody effects persisted for up to eleven weeks depending upon the volume of plasma given, which had a half-life of about 12 days. The infusions were followed by fewer symptoms, a transient increase in T lymphocytes, a reduction in the frequency of opportunistic infections, and a decline in the rate at which HIV could be cultured from plasma or lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901518     DOI: 10.1016/s0140-6736(88)90468-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  35 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 2.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

Review 3.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

4.  Immunotherapy for infectious diseases.

Authors:  J E Pennington
Journal:  West J Med       Date:  1990-04

5.  Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.

Authors:  V Boyer; H Broly; S Souche; P Madaule; J Rossier; D Zagury; C Desgranges
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

6.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 7.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 8.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

9.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.

Authors:  K J Hasenkrug; D M Brooks; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

Review 10.  Does intravenous immune globulin have a role in HIV-infected patients?

Authors:  P L Yap
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.